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In 1991 the International Collaborative Group on Hereditary Non
Polyposis Colorectal Cancer (ICG-HNPCC) defined the Amsterdam
I clinical criteria for identifying HNPCC families. The following 4
criteria must be fulfilled: 1) At least 3 family members in at least 2
generations should have histologically verified colorectal cancer;
2) One family member must be under the age of 50 at the time of
diagnosis; 3) One family member must be first degree relative of
the 2 others; 4) FAP must be excluded (Vasen et al, 1991). Based
on a high incidence of CRC in the Western world, we hypothe-
sized that coincidental clustering of CRC among relatives of
young colorectal cancer patients might explain a considerable
fraction of the families who fulfil the Amsterdam criteria I. 
PATIENTS AND METHODS 
Purpose 
The aim of this study was to estimate the number of coincidental
Amsterdam criteria I positive families in a sample of non-selected
CRC patients younger than 50 years of age. We also wanted to
estimate the expected proportion of coincidental Amsterdam
criteria I positive families among young patients’ families meeting
the Amsterdam criteria I. 
Patients 
The study was designed as a prospective population-based multi-
centre study. Consecutive Danish patients with primary adenocar-
cinoma of the colon and rectum diagnosed before the age of 50,
with official address in a participating county, were invited to
participate. Written informed consent was required to include a
patient, and the study was approved by the local ethical
committee. 4 Danish counties (population 1.4 million, 26% of the
Danish population) were successively included in the study from
November 1995 to October 1998. (County of Aarhus was in-
cluded November 1995, County of Ribe – August 1996, County of
Ringkoebing – March 1997 and County of Viborg was included
August 1997.) All Danish CRC patients are diagnosed and treated
in the public health care system, and lists of all CRC patients from
the Institutes of Pathology covering the area were checked regu-
larly to ensure that no CRC patients were missed. 
Family history 
The surgeons filled in a questionnaire covering malignancy and
age at time of diagnosis among family members, and the study
group interviewed all patients about sex, current age or age at time
of death for all first and second degree relatives. Hospital files,
death certificates or information from the Danish Cancer Registry
were requested on each family member with a possible HNPCC
related cancer. 
Statistical methods 
For each family the probability of meeting the Amsterdam Criteria
I by chance was calculated using a specific FORTRAN program
developed by the study group. The calculations were based on the
age-and sex-specific incidence data from the Danish Cancer
Registry for the year 1990 (Storm et al, 1994). 
The Amsterdam criteria I, can be met through 7 different paths
(Figure 1). Path 1 includes the patient, the parents and the grand-
parents. Path 2 includes the patient, the parents and the patient’s
children. It is clear that 5 additional paths exist, #3 to #7 in Figure 1. 
The probability that a young colorectal cancer patient’s family
meets the Amsterdam criteria I by chance depends on the number
of first and second degree relatives, their sex and current age or
age at death and on the cumulative incidence rate of colorectal
cancer in the background population. 
If a patient is able to supply the above information for his/her
parents and grandparents, the Amsterdam criteria I can be met in 4
different ways through path #1 (patient + patient’s father +
patient’s father’s father or father’s mother or patient + patient’s
mother + patient’s mother’s father or mother). Information about
any children generates new combinations through path #2. These
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principles continue through path #3–#7. The probabilities from the
various paths are combined to yield the family’s probability of
meeting the Amsterdam criteria I. 
RESULTS 
Families meeting the Amsterdam criteria I 
Among 1514 consecutive CRC patients, 87 (5.7%) were diag-
nosed before the age of 50. 77 patients (88.5%) were interviewed,
and 4 families met the strict Amsterdam criteria I. Another 2 families
did not meet the strict criteria due to lack of a verified diagnosis in
a third family member. In one family, the third tumour was located
at the splenic flexure detected on X-ray examination. Histology
from metastasis showed adenocarcinoma. In another family the
third family member had a big abdominal tumour and blood in the
stool. Histology showed mucinous adenocarcinoma consistent
with colorectal cancer. Hence for all practical purposes 6 families
(6/77 = 7.8%) met the Amsterdam criteria I. By including the 2
family members described above, we observed 24 CRC cases in
the 6 families, and all cases were histologically verified. 
Probability calculations 
77 patients (77/87 = 88.5%) supplied information about current
age or age at the time of death and sex among 1407 first and
second degree relatives (an average of 18.3 members per family). 
Every family’s probability of meeting the Amsterdam criteria I
by chance was calculated. The 77 families’ risk of sporadically
meeting the Amsterdam criteria I ranged from 0.0% to 7.1%, the
average chance being 1.1%. 13 of the 77 families (17%) had a
more than 2% risk of meeting the Amsterdam criteria I by coincid-
ence. 
In this sample of 77 families the estimated chance of sporadic
fulfilment of the Amsterdam criteria I corresponds to an expecta-
tion of 0.83 family. The chances of finding at least 1, 2 or 3
Amsterdam I positive families follow a binomial distribution and
these are 56.7%, 20.2% and 5.1% respectively. The probabilities
of finding 4, 5 or 6 positive families are 1.0%, 0.2% and 0.02%,
respectively. In this sample of 77 families, the median expected
number of families meeting the Amsterdam criteria I by coincid-
ence is 1 (95% confidence limits 0–3). 
DISCUSSION 
In this study the chance of a family meeting the Amsterdam
criteria I by coincidence, has been quantified for the first time on
real families. 6 out of 77 families (7.8%) met the Amsterdam
criteria I. We estimated a 0.02% probability of finding 6 or more
families due to coincidental clustering in this material, so it is very
unlikely that all 6 families are coincidental. Pathogenic mutations
in the genes hMLH1 or hMSH2 are detected in approximately
50% of the families that meet the Amsterdam criteria I, and in
8–28% of suspected HNPCC families depending on which criteria
of suspicion that are used (Buerstedde et al, 1995; Moslein et al,
1996; Viel et al, 1997; Wijnen et al, 1998; Park et al, 1999).
Therefore we would not expect that all families would meet the
criteria by coincidence. 
Our calculations show, that when 77 young CRC patients are
interviewed, there is a 56.7% chance of finding at least 1 family
meeting the criteria. There is a 20.2% risk of finding 2 or
more families by coincidence, and a 5.1% risk of finding 3 or more
families that meet the criteria by coincidence. Hence, the most
likely outcome is, that 1 out of our 6 families (17%), is the result of
coincidental aggregation of CRC among family members. 
The 6 families who met the Amsterdam criteria I were screened
for hMLH1/hMSH2 mutations by SSCP, HD and PTT (data not
shown). We have previously shown that the combination of using
SSCP and HD are highly sensitive for the detection of
hMLH1/hMSH2 mutations (Wikman et al, 2000). We detected
mutations in 2 out of the 6 families, leaving us with 4 unexplained
families. Therefore, the risk of meeting the Amsterdam criteria I
by chance in mutation negative families is more likely 1 in 4
(25%) than the 1 in 6 (17%) risk that we have demonstrated on the
Amsterdam criteria I positive families where mutational status is
not taken into account. 
The calculations are based on the assumption of a low propor-
tion of hereditary CRC cases among the total number of CRC
cases in Denmark and that environmental exposures and dietary
habits are similar in Danish families. 
We recommended all 6 families to follow the surveillance
programme proposed by ICG-HNPCC. It is impossible to distin-
guish between HNPCC families and families who meet the criteria
by coincidence, unless a pathogenic mutation has been detected. 
Our results show that the majority of families of young CRC
patients, who meet the Amsterdam criteria I are likely to be due to
a genetic predisposition, but a considerable fraction of the families
can be explained by chance aggregation of CRC in family
members. 
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